Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID

NCT06631287 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

550

Enrollment

OTHER

Sponsor class

Conditions

Long COVID
Sars-CoV-2 Infection
Coronavirus Infections
COVID-19

Interventions

DRUG: Baricitinib
OTHER: Placebo

Sponsor

Wes Ely

Collaborators

[object Object]
[object Object]